5402222025-04-012025-06-305402222025-04-012025-06-30in-capmkt:OtherExpenses1Member5402222025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares540222LAURUSLABSNOTLISTEDINE947Q01028LAURUS LABS LIMITEDMain BoardEquity2025-04-012026-03-312025-07-252025-07-09INRCroresQuarterlyFirst quarterSingle segmentManufacturer of Generics API, Generics FDF, Synthesis and Bio Technology2025-07-2514:00:002025-07-2514:55:00Not applicablefalsefalseNo default by the Company.2025-04-012025-06-30UnauditedStandalone14327500000215200000145427000005728900000385000000-118000001799000000438900000935700000315260000012428300000211440000002114400000596600000-616000005350000000157940000000001579400000-19000001577500000107960000022.932.93002.932.931. The above standalone unaudited financial results of Laurus Labs Limited (the Company) has been reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on July 25, 2025. <BR> 2. These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI). <BR> 3. The Company is engaged in the manufacture and sale of Pharmaceuticals which constitutes a single reportable business segment as per Ind AS 108 Operating Segments. During the quarter ended June 30, 2025, the Company allotted 572,408 equity shares of Rs 2 each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. <BR> 4. During the quarter ended June 30, 2025, the Company allotted 572,408 equity shares of Rs 2 each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme. <BR> 5. The figures for the quarter ended March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and published year to date figures up to third quarter of the financial year ended March 31, 2025, which were subject to limited review by the statutory auditors.Other Expenses3152600000Remeasurement gains/(losses) on defined benefit plans-2500000-2500000-6000000-1900000